ERBB2 and gastric adenocarcinoma: The phase III KEYNOTE-811 trial demonstrated a superior ORR for chemotherapy plus trastuzumab and pembrolizumab compared to chemotherapy plus trastuzumab alone as a first-line therapy for HER2-positive gastroesophageal junction and gastric adenocarcinoma [20].